

RECEIVED


SEP 09 2003

OFFICE OF PETITIONS

PATENT

Attorney Docket No. 015280-259120US

Client Ref. No. E-002-96/3



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PASTAN, Ira et al.

Application No. 09/684,599

Filed: October 5, 2000

For: MESOTHELIN, A DIFFERENTIATION  
ANTIGEN PRESENT ON MESOTHELIUM,  
MESOTHELIOMAS AND OVARIAN  
CANCERS AND METHODS AND KITS  
FOR TARGETING THE ANTIGEN

Confirmation No. 2466

Examiner: Unger, Susan

DECLARATION OF  
ROBYN HESS

Commissioner For Patents  
P.O. Box 1450  
Arlington, VA 22313-1450

Sir:

I, ROBYN HESS, hereby declare as follows:

1. I am the Manager of the International and Docketing Department for the firm of Townsend and Townsend and Crew LLP, ("Townsend").
2. My business address is: Townsend and Townsend and Crew, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111.
3. I have been continuously employed by Townsend since March 1998.
4. The Townsend procedure for handling U.S. Patent and Trademark Office ("PTO") mail is outlined below:
  - a. All incoming PTO mail is directed to the attention of the U.S. Docketing Department.

RECEIVED

SEP 16 2003


TECH CENTER 1600/2900

b. Using a computerized docketing system, due dates are calendared, and the original document is marked with the Townsend docket number, working attorney initials and response due date, if any. The original PTO document is then forwarded to the working attorney.

5. On or about August 25, 2003, and upon the request of attorney Laurence J. Hyman, I conducted a search of the computer records for any information/documentation relating to the above-identified application. I found no evidence that the firm received any communication from the PTO regarding this application between the filing of Mr. Hyman's Amendment dated June 19, 2002, and the Notice of Abandonment.

6. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: August 25, 2003



Robyn Hess, Manager  
International and Docketing Department

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, CA 94111-3834  
(415) 576-0200

60025344 v1

**TTC Client Docket Report****Results for: 015280****8/16/2002 - 8/25/2007****1 Records Found!**

Date MatterID	Action/Event Notes	Title/Mark Client	App No Filing Date	Re Is
Due Date: 12/04/2003	Check Abandoned Status	Mesothelin, A Differentiation Antigen Present on Mesothelium, Mesotheliomas & Ovarian Cancers & Methods &...	09/684599	
015280-259120US (Pat)		National Institutes of Health	10/5/2000	

**Patent Property Status Report**Click [here](#) to notify Docke**Download Status Report****Results for:****Records f****015280      National Institutes of Health**

Office of Technology Transfer  
6011 Executive Boulevard  
Suite 325  
Rockville, MD 20852-3804  
(301)-496-7056

TTC Ref Country ATTY(s) Handling	Client's Ref	Title	Inventor	Appl No. Filing Date	Pat No. Issue Date	Status and Remarks
015280- 259120US LJH (GWC)	E-002-96/3Mes	othelin, A Differentiation Antigen Present on Mesothelium, Mesotheliomas & Ovarian Cancers & Methods &...	Pastan, Ira H. Chang, Kai	09/684599 10/05/2000		Pending filing receipt 3/06/01 Response to Notice of Missing Parts (1st Deadline): 02/20/2001 **Completed** Response to Notice to Comply with Sequence Requirements (1st Deadline): 09/30/2001 **Completed** Response to Office Action: 03/19/2002 **Completed**